Parthenolide content of Canadian commercial feverfew preparations: Label claims are misleading in most cases

Canadian Pharmaceutical Journal

Volumn 136, Issue 10, 2003, Pages 23-30

  Draves, Andrew H ^a   Walker, Scott E ^b,c  

^a S/Women's Coll Hlth Sci Ctr ^*

^b Department of Pharmacy   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FEVERFEW 125; FEVERFEW GRAND CAMOMILE; FEVERFEW HERB; FEVERFEW HERB 400; FEVERFEW LEAF; FEVERFEW LEAF AND FLOWER; FEVERFEW LEAF EXTRACT; FEVERFEW LEAVES; HERBAL MIGRAINE FORMULA; METHANOL; MIGRA STRESS; MIGRAGRAND; MIGRAVAN FEVERFEW; MYGRACARE; MYGRAFEW; MYRANON FEVERFEW EXTRACT; NOMIGRAINE MATRICARE; PARTHENOLIDE; STANDARDIZED FEVERFEW LEAF; TANACET 125; TANACETUM PARTHENIUM EXTRACT; WATER;

ACCURACY; CANADA; DOSE RESPONSE; DRUG CAPSULE; DRUG FORMULATION; DRUG LABELING; DRUG MANUFACTURE; HERBAL MEDICINE; LIQUID CHROMATOGRAPHY; PROPHYLAXIS; QUALITY CONTROL; REVIEW; TABLET; TINCTURE; ULTRAVIOLET RADIATION;

EID: 1442300812     PISSN: 08286914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Zink T, Chaffin J. Herbal 'health' products: what family physicians need to know. Am Fam Physician 1998;58:1133-40.
2. Smith M, Boon H. The Pharmacist Training Program in Botanical Medicine. Canadian College of Naturopathic Medicine 1998;121-8.
3. Pattrick M, Heptinstall S, Doherty M. Feverfew in rheumatoid arthritis: a double blind placebo controlled study. Ann Rheum Dis 1989;48:547-9.
4. Miller LG. Herbal medicines: selected clinical considerations focusing on known or potential drug-herb interactions. Arch Intern Med 1998;158:2200-11.
5. Brown D. Herbal Prescriptions for Better Health. Rocklin, CA: Prima Publishing, 1995.
6. Diamond S. Herbal therapy for migraine. An unconventional approach. Postgrad Med 1987;81:197-98.
7. Johnson ES, Kadam NP, Hylands DM, Hylands PJ. Efficacy of feverfew as prophylactic treatment of migraine. BMJ 1985;291:569-73.
8. Murphy JJ, Heptinstall S, Doherty M. Randomized double-blind placebo-controlled trial of feverfew in migraine prevention. Lancet 1988;ii:189-92.
9. Brown D. Feverfew: disappointing results in migraine study. Q Rev Nat Med 1997;4:89-90.
10. Palevitch D, Earon G, Carasso R. Feverfew (Tanacetumparthenium) as a prophylactic treatment for migraine: a double-blind placebo-controlled study. Phytother Res 1997;11:508-11.
11. Kuritzky A, Elhachman Y, Yerushalmi Z, Hering R. Feverfew in the treatment of migraine: its effect on serotonin uptake and platelet activity. Neurology 1994;44(Suppl 2):293P.
12. Pfaffenrath V, Diener HC, Fischer M, Friede M, Henneicke-von Zepelin HH. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis: a double-blind, multicentre, randomized placebo-controlled dose-response study. Cephalalgia 2002;22:523-32.
13. Awang D. Feverfew fever: a headache for the consumer. Herbalgram 1993;29:34-6,66.
14. Heptinstall S, Awang DVC, Dawson BA, Kindack D, Knight DW, May J. Parthenolide content and bioactivity of feverfew (Tanacetum parthenium (L.) Schultz-Bip.). Estimation of commercial and authenticated feverfew products. J Pharm Pharmacol 1992;44:391-5.
15. Vogler BK, Pittler MH, Emst E. Feverfew as a preventative treatment for migraine: a systematic review. Cephalalgia 1998;18:704-8.
16. Ashbury Biologicals, 1996, Tanacet 125 monograph, http://www.bionutrix.com/monographs/tanacet.html, November 28, 1999.
17. Groenewegen W, Knight D, Heptinstall S. Progress in the medicinal chemistry of the herb feverfew. Prog Med Chem 1992;29:217-38.
18. Groenewegen W, Heptinstall S. Amounts of feverfew in commercial preparations of the herb. Lancet 1986;ii:44-5.
19. Awang D, Dawson B, Kindack D. Parthenolide content of feverfew (Tanacetum parthenium) assessed by HPLC and H-NMR spectroscopy. J Nat Prod 1991:54;1516-21.
20. Abourashed EA, Khan IA, Abourashed EA, Khan IA. Determination of parthenolide in selected feverfew products by liquid chromatography. J AOAC Int 2000;83:789-92.
21. Nelson MH, Cobb SE, Shelton J. Variations in parthenolide content and daily dose of feverfew products. Am J Health-System Pharmacy 2002;59:1527-31.